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INTRODUCTION
Patients with early cancers of the esophagus and stomach
have been found to have better prognosis than patients with
advanced cancers. With regard to tumors of the pancreas,
however, there is considerable controversy about the diagno-
sis of early pancreatic cancer. The relationship between the
tumor size and postoperative long-term survival was men-
tioned for the first time in 1964, with pancreatic cancers ≤
2 cm in diameter being classified as small (1). In an analysis
of 106 patients with small pancreatic cancer (≤2 cm in dia-
meter) (2), however, only 44% of tumors were classified as
stage I, remaining within the pancreas, and these patients
did not have better prognosis than those with advanced stage
tumors. It has been suggested that the majority of pancreatic
ductal carcinomas ≤1 cm in diameter are carcinoma in situ
and would therefore have better postoperative prognosis, thus
being early pancreatic cancers (3). In a study of 36 patients
with minute cancers measuring ≤1 cm in diameter, how-
ever, the 5-yr post-pancreatectomy survival rate was only
57% (4).
Most retrospective studies of small pancreatic cancers have
been performed in Japan, with fewer performed in other
countries. Despite the very poor prognosis of patients with
these tumors, there have been no large population-based
studies, especially regarding small-sized pancreatic cancer.
We therefore attempted to identify the clinicopathological
aspects of patients with small pancreatic cancer.
MATERIALS AND METHODS
Inclusion/exclusion criteria
We collected data on patients with pancreatic cancer who
were treated from October 1989 to May 2006 at one univer-
sity hospital. Of the over 700 patients with pathologically
defined pancreatic malignancy, those with conventional duc-
tal pancreatic cancer were enrolled in this study. Patients
with cystic neoplasms, intraductal papillary mucinous neo-
plasms (IPMN), endocrine tumors, and islet cell tumors were
excluded, leaving a total of 542 patients with conventional
pancreatic cancer. 
Study protocol
The whole tumor was sectioned continuously, and the sec-
tions were stained with hematoxylin and eosin and carefully
examined microscopically. Tumor size (TS), capsular inva-
sion, retroperitoneal invasion, invasion to the peripancreatic
tissues, and metastasis to regional lymph nodes were histo-
logically evaluated. The histologic subtype of each tumor
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Clinicopathological Aspects of 542 Cases of Pancreatic Cancer: 
a Special Emphasis on Small Pancreatic Cancer
Small pancreatic cancers (longest diameter ≤ ≤2 cm) have been regarded as pre-
liminary to early pancreatic cancer, which was thought to be highly curable. During
our experience since 1989, we evaluated 542 cases of pancreatic cancer. Among
them we found 74 cases of tumors ≤ ≤2 cm in diameter, small pancreatic cancer
(TS1 pancreatic cancer). Well-differentiated adenocarcinomas (18.9%) and absence
of symptoms (8.1%) were more frequent in patients with TS1 than in those with
larger pancreatic tumors. Only 16 of the 74 patients (21.6%) with small pancreatic
cancers had T1 tumors. According to the International Union Against Cancer (UICC)
staging, only 11 patients (14.9%) were stage IA: their 5-yr survival rate was 23.3%
and their median survival was 30.0 months. Among these 11 patients, 3 had tumors
<1 cm; their median survival time was 30.0 months and their 5-yr survival rate was
50.0%. These findings may indicate that ‘small’ pancreatic cancer is not equivalent
to ‘early’ pancreatic cancer.
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was determined by pathologists well experienced in pancre-
atic cancers.
The TS was categorized by the criteria of the Japan Pan-
creas Society (JPS) as TS1, ≤2 cm; TS2, 2.1-4.0 cm; TS3,
4.1-6.0 cm; or TS4, >6.0 cm, and the tumor location was
categorized as the head, body, or tail. All tumors were staged
according to the International Union Against Cancer (UICC)
6th edition 2004 and JPS staging systems 5th edition 2002,
and tumor (T) and nodal (N) factors were determined by
histologic findings of the resected specimens (pathological
TNM classification).
Initial patient symptoms were evaluated relative to the
tumor size; if patients presented with more than one symp-
tom, the chief complaint was selected by a chart review. Tu-
mor markers, including CA19-9 and carcinoembryonic anti-
gen (CEA), were evaluated relative to the tumor size, and
their concentrations at the inifial detection of the tumor were
determined. 
Statistical analysis
The cumulative survival rate was calculated using the Ka-
plan-Meier method. Log-rank test was used to evaluate dif-
ferences between survival curves and to check statistical sig-
nificance. p values less than 0.05 were considered statistical-
ly significant. All analyses were performed using Statistical
Package for the Social Sciences (SPSS), version 13.0 (SPSS
Inc., Chicago, IL, U.S.A.).
RESULTS
Baseline characteristics of the patients
We identified 74 patients (45 men and 29 women) with
small pancreatic cancer, defined as having the longest diameter
≤2 cm regardless of stage, ranging in age from 35 to 77 yr
(mean age, 57.6 yr). Sixty-five tumors (87.8%) were located
in the head of the pancreas, 7 (9.5%) in the tail, and 2 (2.7%)
in the body. Seventy-four patients out of 78 (94.8%) under-
went pancreatectomy (37 pylorus-preserving pancreaticoduo-
denectomy or Whipple’s operation, 17 distal pancreatecto-
my, 9 pancreaticoduodenectomy, and 11 total pancreatecto-
my) and others palliative resection or just surgical biopsy.
Histologic classification TS1 TS2 TS3 TS4 Total p value
Papillary adenocarcinoma 0 2 (0.7%) 5 (4.3%) 1 (1.9%) 8 (1.5%) 0.09
Tubular adenocarcinoma
Well-differentiated 14 (18.9%) 38 (12.8%) 12 (10.3%) 3 (5.6%) 67 (12.4%) <0.01
Moderately differentiated 45 (60.8%) 195 (65.4%) 67 (57.8%) 35 (64.8%) 342 (63.1%) <0.01
Poorly differentiated 8 (10.8%) 47 (15.8%) 16 (13.8%) 7 (13.0%) 78 (14.4%) <0.01
No information of differentiation 5 (6.8%) 0 0 0 5 (0.9%) < 0.01
Adenosquamous carcinoma 1 (1.4%) 0 2 (1.7%) 0 3 (0.6%) 0.63
Mucinous carcinoma 1 (1.4%) 11 (3.7%) 8 (6.9%) 6 (11.1%) 26 (4.8%) <0.01
Anaplastic carcinoma 0 0 1 (0.9%) 2 (3.7%) 3 (0.6%) 0.63
Undifferentiated carcinoma 0 5 (1.7%) 5 (4.3%) 0 10 (1.8%) 0.02
Total 74 (100%) 298 (100%) 116 (100%) 54 (100%) 542 (100%)
Frequency 13.7% 55.0% 21.4% 10.0% 100%
Table 1. Histologic subtypes of invasive cancers according to the tumor size (TS)
TS1, ≤2.0 cm; TS2, 2.1-4.0 cm; TS3, 4.1-6.0 cm; TS4, >6.0 cm.
Initial symptom TS1 TS2 TS3 TS4 Total p value
No symptoms 6 (8.1%) 17 (5.7%) 6 (5.2%) 1 (1.9%) 30 (5.5%) <0.01
Abdominal pain 31 (41.9%) 130 (43.6%) 55 (47.4%) 34 (63.0%) 250 (46.1%) <0.01
Indigestion 5 (6.8%) 29 (9.7%) 17 (14.7%) 7 (13.0%) 58 (10.7%) <0.01
Nausea & vomiting 0 2 (0.7%) 0 0 2 (0.4%) 0.25
Jaundice 27 (36.5%) 89 (29.9%) 27 (23.3%) 9 (16.7%) 152 (28.0%) <0.01
Weakness 0 8 (2.7%) 0 1 (1.9%) 9 (1.7%) <0.01
Palpable mass 0 5 (1.7%) 4 (3.4%) 0 9 (1.7%) 0.04
Back pain 1 (1.4%) 3 (1.0%) 0 2 (3.7%) 6 (1.1%) <0.01
Exacerbation of diabetes 1 (1.4%) 5 (1.7%) 0 0 6 (1.1%) <0.01
Weight loss 3 (4.1%) 8 (2.7%) 7 (6.0%) 0 18 (3.3%) <0.01
Dizziness 0 1 (0.3%) 0 0 1 (0.2%) NS
Diarrhea 0 1 (0.3%) 0 0 1 (0.2%) NS
Total 74 (100%) 298 (100%) 116 (100%) 54 (100%) 542 (100%)
Table 2. Initial symptoms of the patients according to the tumor size (TS)
TS1, ≤2.0 cm; TS2, 2.1-4.0 cm; TS3, 4.1-6.0 cm; TS4, >6.0 cm.Small Pancreatic Cancer in Korea S81
Histologic subtypes
We identified a total of 542 patients with pancreatic can-
cer (all sizes); their histologic subtypes are shown in Table 1.
The frequency of well-differentiated adenocarcinoma was
higher in TS1 than in larger size tumors (TS2 and TS3) and
was significantly higher in TS1 and TS2 than in TS4 tumors
(p<0.01). The most frequently observed histologic subtype
was moderately differentiated adenocarcinoma. The frequen-
cy of poorly differentiated adenocarcinomas was significant-
ly higher in TS2 and TS3 tumors (p<0.01).
Symptoms 
Initial symptoms according to the tumor size are shown in
Table 2. Abdominal pain was the most frequent symptom
(46%), followed by jaundice (28.0%). Similar findings were
observed in patients with small pancreatic cancer. Interest-
ingly, patients without any symptoms were more frequent
in TS1 than in larger tumors. 
Tumor extent
In the JPS classification system, the local extent of the tu-
UICC T stage JPS T stage UICC N UICC stage
T0 0 T0 0 N0 40 (54.1%) IA 11 (14.9%)
T1 16 (21.6%) T1 16 (21.6%) N1 34 (46.0%) IB 0
T3 54 (73.0%) T3 41 (55.4%) JPS N IIA 24 (32.4%)
T4 4 (5.4%) T4 17 (23.0%) N0 40 (54.1%) IIB 19 (25.7%)
N1 21 (28.4%) III 7 (9.5%)
CH 41 (55.4%) UICC M N2 10 (13.5%) IV 13 (17.6%)
DU 20 (27.0%) M0 61 (82.4%) N3 3 (4.1%)
S 5 (6.8%) M1 13 (17.6%) JPS stage
RP 39 (52.7%) I 11 (14.9%)
PV 9 (12.2%) JPS M II 1 (1.4%)
A 4 (5.4%) M0 72 (92.3%) III 38 (51.4%)
PL 1 (1.4%) M1 2 (2.7%) IVa 17 (23.0%)
OO 7 (9.5%) IVb 7 (9.5%)
Table 3. Extent of disease in 74 patients with TS1 cancer
TS1, tumor size; UICC, International Union Against Cancer; JPS, Japan Pancreas Society; CH, distal bile duct invasion; DU, duodenal invasion; S,
serosal invasion; RP, retropancreatic tissue invasion; PV, portal venous system invasion; A, arterial system invasion; PL, extrapancreatic nerve plexus
invasion; OO, invasion of other organ.
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Fig. 1. UICC T factor and survival rate after pancreatectomy for
TS1 pancreatic cancer. T1, tumor limited to the pancreas, ≤2 cm
in its greatest diameter; T3, tumor extending beyond the pancreas
but without involvement of the celiac axis or superior mesenteric
artery; T4, tumor involving the celiac axis or superior mesenteric
artery (total p value <0.05).
T3
T4
T1-censored
T3-censored
N Median 5-yr survival p value
T1 16 30.0 19.1%  0.28
T3 54 20.0 15.0% 
0.02 T4 4 5.0 0%
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Fig. 2. JPS T factor and survival rate after pancreatectomy for TS1
pancreatic cancer. T1, tumor limited to the pancreas, ≤2 cm in
its greatest diameter; T3, tumor extending into the bile duct, duo-
denum, or peripancreatic tissue; T4, tumor extending into the ad-
jacent large vessels, extrapancreatic nerve plexus, or other organs
(total p value <0.05). 
T3
T4
T1-censored
T3-censored
T4-censored
N Median 5-yr survival p value
T1 16 30.0 19.1% 
0.45
T3 41 23.0 19.2% 
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mor (T factor) is graded according to 9 factors: tumor size and
invasion of the distal bile duct, duodenal, serosal, and retro-
pancreatic tissue, portal venous system, arterial system, extra-
pancreatic nerve plexus, and other organs. Lymph node me-
tastasis (N factor) is divided into 3 groups, and distant metas-
tasis (M factor) includes N3 lymph node metastasis. In the
UICC classification system, T4 is decided by arterial invasion
other than T4 of JPS, and lymph node metastasis is graded as
N0 or N1. The positive rate of each factor and the resulting
stages in patients with TS1 are summarized in Table 3. 
Tumor markers
CA19-9 concentrations averaged 344±1,209 U/mL in
patients with TS1 tumors, 568±2,129 U/mL in TS2, 448
±914 U/mL in TS3, and 3,780±15,574 U/mL in TS4.
CA19-9 concentrations are largely dependent on bile duct
strictures rather than cancer itself (5). After excluding pati-
ents with bile duct strictures, CA19-9 concentrations aver-
aged 466±1,466 U/mL in patients with TS1 tumors, 617
±2,714 U/mL in TS2, 313±736 U/mL in TS3, and 3,986
±16,907 U/mL in TS4. We also found that CEA concentra-
tions were 3.85±4.66 ng/mL in patients with TS1 tumors,
5.15±14.25 ng/mL in TS2, 17.72±103.17 ng/mL in TS3,
and 243.15±634.18 ng/mL in TS4. Thus, these tumor mark-
ers did not differ with respect to the tumor size, except for
TS4.
Tumor staging and survival
Fig. 1 shows the survival rate relative to UICC T stage.
Patients with T1 tumors had a median survival time of 30.0
months and a 5-yr survival rate of 19.1%. When these pati-
ents were classified according to the JPS classification, their
survival curves differed slightly (Fig. 2). In the UICC system,
T4 indicates tumor invasion of the celiac or superior mesen-
teric artery, whereas JPS T4 is not necessarily indicative of
arterial invasion. Fig. 3 shows the influence of lymph node
metastasis on TS1 patient survival after pancreatectomy,
while Fig. 4 shows the relationship between JPS stage and
survival after pancreatectomy. Only one patient was stage
II, so the p value relative to other stages could not be calcu-
lated. Even patients with stage IA tumors, however, had a
median survival time of only 30.0 months and a 5-yr survival
rate of only 23.3%. When these patients were classified by
the UICC staging system (Fig. 5), there was an inversion of
prognosis between stage IIB and stages III and IV. In patients
with stage III disease and TS1 tumors, T4 invasion should
worsen the survival. In addition, only a small number of
patients (N=7) had stage III disease. 
Early pancreatic cancer 
Since early pancreatic cancer has not been well defined,
we classified early pancreatic cancers as those with the longest
diameter <1 cm or carcinoma in situ, as suggested by Ariya-
ma et al. (3). Of the eleven patients with UICC stage IA tu-
mors, only three patients had tumors <1 cm in diameter, all
of which were carcinoma in situ such as PanIN-3. These
accounted for a very small proportion of total pancreatic can-
cer (3/542:0.55%) and small pancreatic cancer (3/74:4.05
%) patients, but they showed a better prognosis than other
TS1 patients. One died 9 yr after curative resection, whereas
another died of malabsorption due complications of Whip-
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
0.00 20.00 40.00 60.00 80.00 100.00 120.00 140.00
Time (months)
No
N (JPS)
Fig. 3. JPS N factor and survival rate after pancreatectomy for TS1
pancreatic cancer. The grouping of the lymph nodes is described
elsewhere (total p value >0.05). 
N1
N2
No-censored
N1-censored
N2-censored
N3-censored N3
N Median 5-yr survival p value
N0 40 25.0 21.7% 
0.39
N1 21 12.0 10.6%
0.65
N2 10 17.0 13.3% 
0.89 N3 3 22.0 0%
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Fig. 4. JPS stage and survival rate after pancreatectomy for TS1
pancreatic cancer (total p value >0.05). 
Stage II
Stage III
Stage I-censored
Stage II-censored
Stage III-censored
Stage IVa-censored Stage IVa
Stage IVb-censored Stage IVb
N 5-yr survival p value
Stage I 11 23.3%
0.30
Stage II 1 -
0.68
Stage III 38 19.7%
0.19
Stage IVa 17 16.1%
0.33 Stage IVb 7 0%ple’s operation. The third patient to underwent surgery about
6 months ago, and she remains alive and in good health.
When we divided UICC stage IA cancers into those <1
cm in diameter (subgroup A) and those 1-2 cm in diameter
(subgroup B), we found that their 5-yr survival rates were
50% and 0%, respectively. One patient in the subgroup A,
however, died not of pancreatic cancer itself but of compli-
cations of Whipple’s operation (30 months after the opera-
tion); if this patient had been excluded, the 5-yr survival rate
of the subgroup A would have been close to 100% (Fig. 6).
However, the same assumption could be possible in subgroup
B patients. 
DISCUSSION
Since the relationship between the tumor size and postop-
erative long-term survival was first proposed (1), there have
been many studies on this subject. In a retrospective evalua-
tion of 106 patients with ‘‘small’’ pancreatic cancer (≤2 cm
in diameter) from the Japanese registry, the 5-yr survival rate
was only 30% (2). In a meta-analysis of 302 patients with
small pancreatic cancer worldwide, an average of 42% of
tumors per study were stage I, and the postoperative 5-yr
survival rate in each study was less than 50% (6). In a series
of 25 patients with small pancreatic cancer, it was suggested
that early pancreatic cancer was indicated by tumors ≤1 cm
in diameter and limited to the duct epithelium (3). Howev-
er, a following review suggested that the ordinary type early
pancreatic cancer could be defined as an intraductal adeno-
carcinoma with no or minimal invasion to the stroma, regar-
dless of the size or extent (7). Although the concept of the
PanIN (Pancreatic intraepithelial neoplasia) classification (8)
has been proposed, many papers still describe pancreatic can-
cers as small or early. In addition, it has been suggested that
radical resection with extensive soft tissue clearance might
be more important for prognosis than tumor size alone (9,
10). Degrees of epithelial atypia of the cystic dilated lesions,
corresponding to PanIN classifications, may be important
in the detection of early-stage pancreatic cancers (11, 12).
A retrospective analysis (13) found that the resectability
of TS1 tumors was nearly 89.6%, but the 5-yr survival rate
was only 31.7%. When staged according to the JPS classifi-
cation system, the 5-yr survival rates of patients with stages
1, 2, 3, 4a, and 4b tumors were 20.6%, 3.9%, 37.4%, 23.5%,
and 14.6%, respectively. The median survival time of pati-
ents with stage 1 tumors was 76.8 months, and the 5 yr sur-
vival rate was 57.8%.
From an evaluation of TS1 patients, we found that the 5-yr
survival rates for patients with stages IA, IB, IIA, IIB, III, and
IV tumors were 23.3%, 0%, 20.6%, 12.7%, 0% and 0%,
respectively, and the median survival times were 30.0 months,
12 months, 25.0 months, 10.0 months, 12.0 months, and
17.0 months, respectively (p>0.05 for each comparison).
When we divided stage IA into patients with a tumor diam-
eter <1 cm and those with a tumor diameter 1-2 cm, we
found that the former subgroup had a median survival time
of only 30 months and a 5-yr survival rate of 50.0% (p>0.05).
After excluding one patient who died due to complications
of Whipple’s operation, the 5-yr survival rate in this sub-
group approached 100%. Although our results indicate that
the small size was not associated with better prognosis com-
pared with larger tumors, tumor size <1 cm showed a trend
toward improved prognosis, albeit without a statistical sig-
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Fig. 5. UICC stage and survival rate after pancreatectomy for TS1
pancreatic cancer (total p value <0.05).  
Stage IV
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Stage IIa-censored Stage IIa
Stage IIb-censored Stage IIb
N Median 5-yr survival p value
Stage IA 11 30.0 23.3%
Stage IB 0 -- uncheckable
Stage IIA 24 25.0 20.6% 0.30
Stage IIB 19 10.0 12.7% 0.38
Stage III 7 12.0 0%
0.18 
Stage IV 13 17.0 0% 
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Fig. 6. Minute cancer subgroup A (carcinoma in situ or size <1
cm with minimal invasion to stroma) vs. subgroup B (tumor size
1-2 cm) and survival rate after pancreatectomy for TS1 pancre-
atic cancer. 
Minute Cancer-censored
Tumor size (1-2 cm)-censored
N 5-yr survival p value
Minute cancer 3 50% 0.40
Tumor size 1-2 cm 8 0%nificance. The lack of statistical significance may be due to
the relatively small numbers of patients.
We used both the UICC and JPS classifications in the same
patients. Although the former is used more often worldwide,
it has several limitations (14), including the inability to ade-
quately evaluate the lymph node status without surgical in-
tervention, the inability to determine treatment options from
a patient’s TMN status, and a lack of association with prog-
nosis. In contrast, while the JPS system has shown improved
stratification as well as being more reliable in predicting out-
come (15), it has not been used frequently outside Japan.
Using the UICC classification system, survival curves were
not delineated according to the advancing stage, and there
was an inversion between stage IIB and stages III and IV. In
contrast, the JPS classification showed more reliable survival
curves and results. Although the UICC classification is sim-
pler and easier to understand, the JPS classification may be
more reliable in predicting the outcome. Since the numbers
of patients evaluated in this study were not large enough to
show differences clearly, further studies involving larger num-
bers of patients by both classification systems may provide a
clearer answer.
Despite their limitations, tumor markers such as CEA and
CA 19-9 are now used to screen for hidden malignancies in
the general population. Although about 80% of patients with
pancreatic cancer are positive for serum type 1 chain carbo-
hydrate antigens such as CA19-9, mostly in advanced stages,
false-positive rates are relatively high (20-30%) in patients
with benign hepatobiliary and pancreatic diseases (16). Gen-
erally, high levels of serum tumor markers are associated
with more advanced disease (17, 18). We found that CA19-
9 and CEA levels were higher in patients with TS4 than in
those with smaller tumors. In patients with TS1 tumors,
however, CA19-9 and CEA concentrations were not elevat-
ed (19), suggesting that these markers are limited in the
early detection of pancreatic cancer.
The CA19-9 levels were higher in patients with jaundice
than in those without. Unexpectedly, when we excluded
patients with jaundice, CA19-9 concentrations were decre-
ased in patients with TS3 tumors. Many patients with pan-
creatic cancer show biliary tract involvement; after exclud-
ing these patients, the number of the remaining of patients
was thought to be not sufficient for analysis. 
Most pancreatic cancers are not completely curable because
they are usually detected in advanced stages, with invasion
of adjacent organs or tissues, at which time they are associ-
ated with symptoms. Of our patients, 5.5% had no symp-
toms, and 46.1% had only abdominal pain. Some of the lat-
ter patients underwent esophagogastroduodenoscopy (EGD)
for abdominal pain, but their EGD findings were within
normal limits. In these patients pancreatic cancers were de-
tected by ultrasonography or other modalities several months
later. At that time, however, most of these tumors were al-
ready inoperable. Conventional ultrasonography is limited
by visualization difficulties in the presence of bowel gas or
obesity and by its range of resolution (20, 21). 
In conclusion, small pancreatic cancers, ≤2 cm in diame-
ter, have a poor prognosis, indicating that small pancreatic
cancer is not equivalent to early pancreatic cancer. Smaller
sized tumors, <1 cm in diameter, had slightly better prog-
nosis than larger tumors, so early detection of these small
tumors is important. 
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